Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates

Kymera Therapeutics

05/08/2026 12:15

Overview
US biopharma firm's Q2 collaboration revenue rose sharply, beating analyst expectations
Net loss for Q2 narrowed compared to prior year
Company ended Q2 with $1.5 bln in cash, runway into 2029

Outlook
Kymera expects topline data from KT-621 Phase 2b AD trial by year-end 2026
Company plans to initiate KT-621 Phase 3 AD trials by mid-2027
Data from KT-621 Phase 2b asthma trial expected in late 2027

Result Drivers
MILESTONE PAYMENTS - Q2 collaboration revenue was driven by a $45 mln option exercise fee from Gilead and a $20 mln milestone payment from Sanofi
R&D INVESTMENT - Higher research and development expenses were primarily due to increased investment in the STAT6 program and growth in the R&D organization

Company press release: ID:nGNX3P2kt3

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
Beat
$65 mln
$31.17 mln (20 Analysts)
Q2 Loss Per Share
 
$0.62
 
Q2 Net Loss
 
$61.21 mln
 
Q2 Operating Expenses
 
$140.61 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Kymera Therapeutics, Inc. is $128.00, about 22.6% above its August 4 closing price of $104.39

Reuters Recommended Reads
Aug 4 - Gilead second-quarter sales rise 8%, beating Wall Street estimates
Aug 3 - Stoke Therapeutics Q2 revenue falls 33% on lower collaboration, licensing income
Aug 4 - Tyra Biosciences Q2 net loss widens on higher R&D expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)